(TXA 2 ), and their mimetics contract vascular smooth muscle from many different species and vascular beds.
1 " 3 These effects are thought to be mediated by stimulation of specific cellular T X A J / P G H J receptors. However, ionophoric activity of the TXA 2 /PGH 2 mimetic 155-hydroxy-9a, l l a -(epoxymethano)prosta-5Z,13£-dienoic acid (U44069) has been demonstrated. 4 -3 U44069 increases canine pulmonary vascular tone by releasing Ca 2+ from an intracellular, tightly bound source. 6 Similarly, U44069 activates rabbit aortic smooth muscle by liberating Ca 2+ from a high-affinity intracellular pool as well as by activating a Ca 2+ influx pathway. 7 Use of a specific TXA 2 /PGH 2 receptor antagonist to antagonize the TXA 2 mimetic-induced 43 Ca 2+ efflux in vascular smooth muscle has not been reported. 6 Such a study could support the idea that these effects are receptor mediated and not the result of ionophoric activity.
The availability of a pure culture of nonembryonic human vascular smooth muscle cells would allow for characterization of human vascular TXA 2 receptors, in particular their structure, function, and the mechanism by which TXA 2 mimetics produce their vasoconstrictor effects. In this study, vascular smooth muscle cells were cultured from human saphenous vein explants, and the effects of the TXA 2 mimetic 15S-hydroxyl l a , 9a-(epoxymethano)prosta-5Z, 13£-dienoic acid (U46619) 8 and the specific TXA^PGHj receptor antagonist 9,11 -dimethylmethano-11,12 methano-16-(3-Iodo-4-hydroxypheny 1)-13,14 dihydro-13-aza-15a/3-co-tetranor-TXA 2 9 on 45 Ca 2+ efflux from these cells were determined (I-PTA-OH).
Materials and Methods
Dulbecco's minimal essential medium (DMEM), trypsin-EDTA and antibiotic-antimycotic mixture (10,000 U/ml penicillin, 25 /xg/ml amphotericin B, 10 mg/ml streptomycin) and fetal calf serum were purchased from Gibco, Grand Island, N.Y. Corning culture flasks and centrifuge tubes were purchased from Fisher Scientific, Pittsburgh, Penn.
45 CaCl 2 was purchased from Amersham, Arlington Heights, 111. U46619 was purchased from Upjohn Co., Kalamazoo, Mich. I-PTA-OH was synthesized as previously described. 9 Rat tail collagen was purchased from Sigma Chemical Co., St. Louis, Mo. Human Serum from coronary artery bypass procedures was deheparinized and defibrinated in the laboratory of Dr. John Lazarchick, Medical University of South Carolina, Charleston, S.C., and stored at -20° C before being sterile filtered through 0.4-/xm Gelman filters and added to culture media. Phosphate buffered saline (PBS) was prepared by adding 1.2 mM NaHPO 4 to 0.85% NaCl (wt/vol) and adjusting the pH to 7.4 with hydrogen chloride.
Culture of Vascular Smooth Muscle Cells
Smooth muscle cells were cultured using a modification of the method of Ross. 10 Unused portions of human saphenous veins from aorto-coronary bypass operations were briefly maintained in sterile lactated Ringer's buffer at room temperature. The vein segments were placed in sterile petri dishes under a laminar flow hood and dissected into 3-4-mm squares and placed intima side down on Corning 25-cm 2 culture flasks previously coated with collagen. The flasks were capped and inverted for 30 minutes, righted, and 2.5 ml of DMEM culture medium supplemented with 10% v/v human serum was added. The flasks were capped loosely and incubated at 37° C in a humidified atmosphere of 95% air-5% CO 2 . The growth medium was exchanged every 48 to 72 hours. Confluent cells were passaged by washing the adherent cells twice with sterile PBS followed by the addition of 0.05% trypsin-EDTA for 5 minutes to loosen the cells from the matrix. The activity of the trypsin was halted by the addition of an equal volume of human serum. The resulting cell suspension was centrifuged at lOOg for 10 minutes and distributed into new culture flasks at a 1:4 subculture ratio. All experiments were performed on cells cultured from a single patient between passage numbers 8 and 12 ( Figure 1) .
The smooth muscle cell cultures generated from the explants displayed a doubling time of approximately 48 hours. The explanted cells displayed positive cytoplasmic staining for the presence of smooth muscle myosin (the antiserum against smooth muscle myosin was a gift from Dr. Mark Willingham of the National Institutes of Health, Bethesda, Md.). Cultured fibroblasts (GM 0037 and GM 5758 obtained from the NIGMS Human Genetic Cell Repository, Camden, N.J.) served as a control and were negative for the presence of smooth muscle myosin. Ultrastructural examination of the cultured smooth muscle cells revealed abundant cytoplasmic filaments resembling myofilaments. The cultures retained the above properties at passage numbers 4, 9, and 12. free DMEM overnight. Uptake of 45 Ca 2+ reached equilibrium by 5 hours (data not shown). Prior to the experiments, flasks were rinsed for 18 minutes with experimental buffer. For measurement of 4i Ca 2+ efflux, 2 ml aliquots of experimental buffer were added to each 25-cm 2 flask of cells and exchanged with fresh buffer at two-minute intervals for 26 minutes. U46619 (50 mM) and I-PTA-OH (5 mM) stock solutions in ethanol were diluted in experimental buffer to appropriate concentrations and added to the flasks during minutes 32-38. Desaturation was commenced simultaneously in up to six 25-cm 2 flasks of 43 Ca 2+ labelled cells. Cell viability at the end of the washout experiments was 96 ±0.6% in 20 /I.M U46619 and 99 ± 0.3% in 20 fxM U46619 plus 5 FXM I-PTA-OH as assessed by trypan blue exclusion (n = 4 each). Each aliquot (2 ml) of buffer was counted in a Beckman (Fullerton, Calif.) liquid scintillation spectrometer. The cells were dissolved in 1 N NaOH overnight and assayed for protein using the method of Lowry."
Statistical Analysis
A natural log transformation of the 45 Ca 2+ desaturation curves was used to obtain linear plots. The trapezoid rule for area under the curve (AUC) was used to measure the magnitude of 45 (ANOVA) of repeated measures and compared to the AUC values using Fisher's protected LSD test.
l2 Doseresponse studies were analyzed using a log-logit transformation followed by a linear regression analysis from which the EC50 (the concentration required to produce a half-maximal response) was determined. Data are expressed as mean ± SEM. (Figure 1 ). The initial rapid component had a t w of 2 minutes (k = 0.35 minutes" 1 ). The remaining slower component of efflux had a t^ of 5.7 minutes (k = 0.12 minutes"')-All experimental agents were added to the buffer medium at 30 minutes, and the resulting changes in 45 Ca 2+ efflux represent effects on this highaffinity, slowly equilibrating pool.
Results

Effects ofKCl and U46619 on 4i Cc?+ Efflux
U46619 (5 /uM) produced an initially rapid 45 Ca 2+ efflux of large magnitude, which quickly tapered and returned to baseline (Figure 2 ). Potassium chloride (40 mM) stimulated 45 Ca 2+ efflux to a lesser extent ( Figure  2) . The maximal efflux of 45 Ca 2+ induced by U46619 was significantly greater (p = 0.006) than that elicited with maximally effective concentrations of potassium chloride. U46619-induced 43 Ca 2+ efflux from vascular smooth muscle cells was dose-dependent with an EC30 of 398 ± 26 nM (n = 4) and a maximally effective dose of 5 fiM (Figure 3 ).
Effects ofl-PTA-OH on U46619-Induced
45 Ca 2+ Efflux The TXA 2 /PGH 2 receptor antagonist I-PTA-OH antagonizes the vasoconstrictor effects of U46619 in human saphenous veins. 13 I-PTA-OH (1 /nM or 5 /AM) added to the medium bathing the vascular smooth muscle cells produced no effects oh 45 Ca 2+ efflux nor did it affect the potassium-chloride-induced increase in 45 Ca 2+ efflux (data not shown). When added prior to U46619, I-PTA-OH attenuated the 45 Ca 2+ efflux (Figure 4) . I-PTA-OH (1 fiM) shifted the U46619 EC M from 398 ± 2 6 nM to 1,353 ±261 nM (p<0.05) (/1 = 4). I-PTA-OH (5 fiM) further shifted the EC50 to 2,031 ± 57 nM (p<0.001) (n = 4).
Discussion
The present study demonstrates TXA 2 /PGH 2 receptor-mediated perturbations of 45 Ca 2+ efflux in a cultured vascular smooth muscle cell line derived from human saphenous veins. These cells demonstrated morphologic, ultrastructural, and immunologic characteristics consistent with vascular smooth muscle cells in culture 10 and retained these characteristics as long as they were maintained in medium supplemented with adult human serum. The cells used were derived from a single subject (subcultures 8-12), but similar results were obtained when using cultured saphenous vein smooth muscle cells from other subjects as well as cultured smooth muscle cells from human internal mammary artery (unpublished data).
We examined the effects of U46619 on the slower component of calcium efflux from these cultured cells. This slow component of efflux is thought to represent the compartment of calcium originating from a highaffinity site within the vascular smooth muscle cell
and is considered the fraction of intracellular Ca 2+ in equilibrium with activator calcium ions. 6 Receptormediated, thromboxane-induced vasoconstriction may be dependent On calcium influx through a calcium channel.
17 U46619 increased the rate of 43 Ca 2+ efflux on the slowly equilibrating component with an ECso of 398 nM. This value differs from the EC*, of 1.7 nM for U46619-induced contractions of human saphenous veins. 13 The reason for the different values is unknown. However, our results are similar to those previously reported for rabbit aorta in which the EC X of U44069 for 45 Ca 2+ efflux was 100 times higher than its ECJO for contracting the tissue. 7 The effect of TXA 2 mimetics on calcium flux may be secondary to an ionophore-like action. 4 -518 The receptor antagonist I-PTA-OH inhibited U46619-induced contraction of human saphenous veins with an IC^of 0.36/iM. 13 I-PTA-OH (1 fiM and 5 /xM) inhibited the U46619-induced 45 Ca 2+ efflux in the cultured vascular smooth muscle cells but had no inhibitory effect on potassium-chloride-induced calcium efflux and was itself devoid of activity. Recently, the thromboxane A 2 antagonist 13-azaprostanoic acid was reported to inhibit thromboxane mimetic-induced calcium influx in rat aortic vascular smooth muscle cells. 19 Thus, evidence suggests that thromboxane receptor-stimulated 43 Ca 2+ efflux and influx in vascular smooth muscle cells is probably mediated by TXAj/PG^ receptors.
Though there is currently a great deal of interest in characterizing the nature of human TXA2/PGH2 receptors, investigations have been limited to studies in platelets. Pharmacologic studies have shown that the T X A J / P G H J receptor in human platelets differs from the TXA 2 /PGH 2 receptor in vascular tissue, 13 but specific biochemical and biophysical studies in the human vascular TXA 2 /PGH 2 receptor are lacking. Of particular importance, in regard to the present study, is that human saphenous vein segments are readily available at the completion of coronary artery bypass graft surgery. Thus, the culturing of these human vascular smooth muscle cells will facilitate studies of vascular TXA2/PGH 2 receptors.
In summary, vascular smooth muscle cells were, for the first time, cultured from human saphenous vein explants. Evidence is presented that the cultured cells retained functional TXA^PGHj receptors since they demonstrated a dose-related perturbation of calcium efflux in response to the TXA 2 /PGH 2 mimetic U46619 which was blocked by the TXAj/PG^ receptor antagonist I-PTA-OH. The availability of cultured smooth muscle cells from nonembryonic vascular tissue makes possible specific observations of vascular TXA 2 /PGH 2 receptor and the subcellular consequences of TXA 2 /PGH 2 stimulation in human vasculature.
